Topic: Pharmacogenomics and Pharmacogenetics of Cancer
Guest Editor(s)
Special Issue Introduction
In the past few years, pharmacogenomics and pharmacogenetics have progressed to predict the efficacy and toxicity of drugs and expanded their role in the management of neoplastic diseases.
The knowledge of somatic molecular alterations in common and rare cancer types is now a recognized component of the cancer treatment decision-making process in clinical trials and practice. Functionally significant cancer somatic gene alterations are in fact of predictive significance of drug response and are also clinically druggable. Secondary gene mutations also drive acquired resistance to target-specific therapy.
The patient's germline genetic variants also contribute to both pharmacokinetic and pharmacodynamic effects of anticancer drugs, affecting the toxicity and efficacy of cancer treatments.
This Special Issue of Cancer Drug Resistance will describe the current status of somatic pharmacogenomics and germline pharmacogenetics in oncology and future trends in these fields.
Original articles and review articles on diagnostic methods, information tools, precision drug discovery and development, pharmacogenetics and pharmacogenomics of specific cancer drug classes, guidelines, and pharmacogenomic biomarkers for precision therapy in various cancer types are welcome.
The knowledge of somatic molecular alterations in common and rare cancer types is now a recognized component of the cancer treatment decision-making process in clinical trials and practice. Functionally significant cancer somatic gene alterations are in fact of predictive significance of drug response and are also clinically druggable. Secondary gene mutations also drive acquired resistance to target-specific therapy.
The patient's germline genetic variants also contribute to both pharmacokinetic and pharmacodynamic effects of anticancer drugs, affecting the toxicity and efficacy of cancer treatments.
This Special Issue of Cancer Drug Resistance will describe the current status of somatic pharmacogenomics and germline pharmacogenetics in oncology and future trends in these fields.
Original articles and review articles on diagnostic methods, information tools, precision drug discovery and development, pharmacogenetics and pharmacogenomics of specific cancer drug classes, guidelines, and pharmacogenomic biomarkers for precision therapy in various cancer types are welcome.
Related Webinar
Submission Deadline
31 Oct 2023
Submission Information
For Author Instructions, please refer to https://www.oaepublish.com/cdr/author_instructions
For Online Submission, please login at https://oaemesas.com/login?JournalId=cdr&SpecialIssueId=CDR230425
Submission Deadline: 31 Oct 2023
Contacts: Lori Kang, Assistant Editor, lori@cdrjournal.com
